Verastem (VSTM) Highlights Phase 1 Duvelisib Combination Data in T-Cell Lymphomas
Tweet Send to a Friend
Verastem, Inc. (NASDAQ: VSTM) today announced the presentation of new preclinical and Phase 1 clinical data from an investigator-sponsored study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
